Increased filaggrin-metabolizing enzyme activity in atopic skin: a pilot study using a canine model of atopic dermatitis

2017 ◽  
Vol 28 (5) ◽  
pp. 479-e111 ◽  
Author(s):  
Natalia Fanton ◽  
Domenico Santoro ◽  
Luisa Cornegliani ◽  
Rosanna Marsella
Keyword(s):  
Atopic Dermatitis ◽  
Enzyme Activity ◽  
Pilot Study ◽  
Canine Model ◽  
Atopic Skin ◽  
Metabolizing Enzyme

Gamisasangja-tang suppresses pruritus and atopic skin inflammation in the NC/Nga murine model of atopic dermatitis

2015 ◽  
Vol 165 ◽  
pp. 54-60 ◽  
Author(s):  
Bo-Kyung Park ◽  
Yang-Chun Park ◽  
In Chul Jung ◽  
Seung-Hyung Kim ◽  
Jeong June Choi ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Murine Model ◽  
Skin Inflammation ◽  
Atopic Skin

scholarly journals Reviewing drug package inserts available in United Arab Emirates for USFDA recommended pharmacogenomic information

2017 ◽  
Vol 2 (1) ◽  
Keyword(s):  
Enzyme Activity ◽  
Genetic Variation ◽  
United Arab Emirates ◽  
Drug Toxicity ◽  
Therapeutic Response ◽  
Drug Efficacy ◽  
Brand Names ◽  
Package Inserts ◽  
Metabolizing Enzyme ◽  
Direct Genetic Evidence

Pharmacogenomics aims to characterize the contribution of genetic polymorphisms to variability in therapeutic response and toxicity. The USFDA has issued a list of drugs which exhibit polymorphism and relevant sections in the package inserts for providing pharmacogenomic information and their biomarkers to reduce the risk of drug toxicity. A total of 67 Package inserts of 41 drugs in 5 therapeutic areas, available in UAE under various brand names, were thoroughly reviewed for direct and indirect pharmacogenomic information and compared with FDA recommendations. It was observed that only 26 package inserts of 17 drugs (41%) prescribed provided direct genetic evidence and information on the type of polymorphism influencing drug efficacy and toxicity. Indirect indicators describing genetic variation in metabolizing enzyme activity was present in 20 inserts (30%)., It was concluded that incorporating the necessary pharmacogenomic information, as recommended by the USFDA, in the package inserts of drugs available in UAE will help in enhancing drug efficacy, safety and awareness among the physicians, pharmacists and patients.

scholarly journals Emollient therapy in children with atopic dermatitis – a pilot study

2020 ◽  
Vol 7 (2) ◽  
pp. 106-115
Author(s):  
Andrzej K. Jaworek ◽  
Magdalena Jaworek ◽  
Przemysław Hałubiec ◽  
Ryszard Kurzawa ◽  
Anna Wojas-Pelc
Keyword(s):  
Atopic Dermatitis ◽  
Pilot Study

scholarly journals CURRENT CONCEPTS OF ATOPIC DERMATITIS IN CHILDREN: PROBLEMS AND PROSPECTS

2019 ◽  
Vol 20 (2) ◽  
pp. 99-107
Author(s):  
Galina I. Smirnova
Keyword(s):  
Atopic Dermatitis ◽  
Immune Responses ◽  
Proinflammatory Cytokines ◽  
Genetic Predisposition ◽  
Allergic Inflammation ◽  
Skin Lesions ◽  
Current Understanding ◽  
Epidermal Barrier ◽  
Barrier Integrity ◽  
Atopic Skin

There are presented modern data describing the current understanding of the pathogenesis of atopic dermatitis (AD): a genetic predisposition to atopy, disruptions of epidermal barrier integrity and a cascade of immune responses, contributing allergic inflammation in the skin. There are both described several mechanisms of acute and chronic phases of AD, the main directions of pathogenetically substantiated treatment of AD in children and indicated the prospects of new preparations specific blockers of proinflammatory cytokines involved in the development of AD - crisaborole, apremilast, dupilumab, lebrikizumab, tralokinumab, tezepelumab. There is especially presented in details external therapy of atopic skin lesions in children with the use of means of modern dermatological cosmetics.

scholarly journals Prospective, Comparative Clinical Pilot Study of Cold Atmospheric Plasma Device in the Treatment of Atopic Dermatitis

2021 ◽  
Author(s):  
Young Jae Kim ◽  
Dong Jun Lim ◽  
Mi Young Lee ◽  
Woo Jin Lee ◽  
Sung Eun Chang ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Pilot Study ◽  
Severity Index ◽  
Skin Lesions ◽  
Treated Group ◽  
Atmospheric Plasma ◽  
Clinical Severity ◽  
Control Treatment ◽  
Cold Atmospheric Plasma ◽  
Plasma Device

Abstract Introduction: Cold atmospheric plasma generates free radicals through the ionization of air at room temperature. Its effect and safety profile in patients with atopic dermatitis have not been evaluated prospectively.Objective: We aimed to investigate the effect and safety of cold atmospheric plasma in patients with atopic dermatitis with a prospective pilot study.Methods: Cold atmospheric plasma treatment or sham control treatment were applied respectively in randomly assigned and symmetric skin lesions. Three treatment sessions were performed at weeks 0, 1, and 2. Clinical severity indices were assessed at weeks 0, 1, 2, and 4 after treatment. Additionally, the microbial characteristics of the lesions before and after treatments were analyzed.Results: We included 22 patients with mild to moderate atopic dermatitis presented with symmetric lesions. We found that cold atmospheric plasma can alleviate the clinical severity of atopic dermatitis. Modified atopic dermatitis antecubital severity and eczema area and severity index score were significantly decreased in the treated group. Furthermore, scoring of atopic dermatitis score and pruritic visual analog scales significantly improved. In microbiome analysis revealed significantly reduced proportion of Staphylococcus aureus in the treated group.Conclusion: Cold atmospheric plasma can significantly improve mild and moderate atopic dermatitis without safety issues.

Sign in / Sign up

Export Citation Format

Share Document